In lung cancer research, CRISPR-Cas9-mediated gene knockout of Bcl-2 interacting cell death suppressor (BIS) has demonstrated a substantial decrease in survival to cisplatin treatment in A549 cells [32]. The gene discussed is BCL2; the disease is lung cancer.